ArticlePloS one2025
Usefulness of using pure β-TCP bone substitute (Neobone) in post-orthopedic implant removal procedures.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe orthopedic implant removal procedure is one of the most commonly performed orthopedic surgeries. This study aimed to compare and report the clinical outcomes between patients who underwent only curettage and those who received pure β-TCP (Neobone®) following curettage.
methodsBetween January 1, 2018, and December 31, 2023, patients at our hospital who underwent implant removal and could be followed for over a year were included in the study. The study encompassed 77 cases.
resultsThe cohort comprised 40 males (51.9%) and 37 females (48.1%) with an average age of 32.5 ± 21.2 years (range 8-69). There were no significant differences between the groups in terms of sex, age, the interval between the first operation and the orthopedic implant removal procedure, locations of operations, or the orthopedic fixation techniques used initially. However, the group undergoing implant removal with β-TCP (Neobone®) bone graft showed statistically significant improvements in performing scar revision procedures simultaneously and in not requiring drain insertion (p = .000).
conclusionsCompared to the group that only underwent curettage, the group treated with pure β-TCP (Neobone®) bone graft required fewer drain placements and more often performed scar revisions simultaneously, facilitating faster healing. While there was no difference in the period for ROM exercises or weight bearing, no refractures occurred in the β-TCP bone substitute group. Hence, the application of pure β-TCP (Neobone®) is clinically advantageous.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.